Physician profile

Steve E Musick

Dermatology · Swansea, IL

NPI 1831176775

$21,944.37

in general payments reported to CMS, 2019-2025

43 companies · $3,435 in 2025

The $3,435 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$10,408.84
Education$366.15

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $3,391.28 2019-2025
Merz North America, INC. $1,993.21 2019-2020
Janssen Biotech, INC. $1,838.04 2019-2025 Tremfya, Stelara, Simponi
Sun Pharmaceutical Industries INC. $1,471.59 2019-2025 Ilumya, Winlevi, Odomzo
Novartis Pharmaceuticals Corporation $1,423.16 2019-2025
Leo Pharma INC. $1,136.60 2019-2025 Adbry, Anzupgo
Amgen INC. $1,134.24 2019-2025 Otezla, Otezla
Lilly USA, LLC $1,075.11 2019-2025 Taltz, Ebglyss, Olumiant
Pfizer INC. $1,035.09 2019-2025
Dermavant Sciences, INC. $851.50 2022-2024 Vtama
Incyte Corporation $773.51 2021-2025 Opzelura
Regeneron Healthcare Solutions, INC. $740.58 2019-2025 Libtayo, Dupixent
E.R. Squibb & Sons, L.L.C. $674.27 2022-2025 Sotyktu
Ucb, INC. $601.78 2019-2025 Bimzelx, Cimzia
Genzyme Corporation $549.33 2019-2025
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Galderma Laboratories, L.P. $506.92 2019-2025 Nemluvio, Aklief, Epsolay
Ortho Dermatologics, A Division of Bausch Health US, LLC $458.28 2019-2023 Arazlo
Mayne Pharma Commercial LLC $268.75 2019-2022
Genentech USA, INC. $162.25 2019-2021
Biofrontera INC. $157.47 2019-2024 Ameluz, Xepi, Bf-Rhodoled
Arcutis Biotherapeutics, INC. $156.44 2023-2025 Zoryve
Sandoz INC. $142.43 2019-2021
Almirall LLC $140.46 2019-2025 Klisyri, Seysara
Allergan, INC. $135.61 2019-2022
Celgene Corporation $125.61 2019
Vyne Pharmaceuticals INC. $109.19 2020-2021
Organon LLC $107.81 2025 Vtama, Nexplanon
Sanofi-Aventis U.S. LLC $91.76 2019-2022
Revance Therapeutics, INC. $89.20 2024-2025 Daxxify
Dermira, INC. $84.30 2019-2021
Epi Health, LLC $75.68 2019-2021
Journey Medical Corporation $67.55 2019-2023
Boehringer Ingelheim Pharmaceuticals, INC. $59.83 2023-2024 Spevigo
Prugen, INC. Pharmaceuticals $59.56 2019-2020
Strata Skin Sciences, INC. $54.98 2019-2025 Xtrac
Verrica Pharmaceuticals INC. $36.46 2023-2024 Ycanth
Encore Dermatology INC. $32.46 2019
Aclaris Therapeutics, INC. $30.20 2019
Mylan Pharmaceuticals INC. $29.28 2019
Dusa Pharmaceuticals, INC. $21.19 2019
Taro Pharmaceuticals USA, INC. $19.92 2019
Mission Pharmacal Company $16.07 2019
Janssen Scientific Affairs, LLC $15.42 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steve E Musick

$21,944.37

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $3,435 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).

https://glasscript.com/doctor/128352/steve-e-musick

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.